Histone deacetylase and histone acetyltransferase inhibitors as antischistosomal agents: a review
10.16250/j.32.1374.2023178
- VernacularTitle:组蛋白去乙酰化酶与组蛋白乙酰转移酶 及其抑制剂抗血吸虫作用研究进展
- Author:
Yuxin WANG
1
;
Jing XU
1
;
Chaoming XIA
1
Author Information
1. Department of Pathogenic Biology, School of Biology & Basic Medical Sciences, Suzhou Medical College of Soochow University, Suzhou, Jiangsu 215123, China
- Publication Type:Journal Article
- Keywords:
Schistosomiasis;
Antischistosomal drug;
Histone deacetylase inhibitor;
Histone acetyltransferase inhibitor
- From:
Chinese Journal of Schistosomiasis Control
2024;36(2):207-214
- CountryChina
- Language:Chinese
-
Abstract:
Schistosomiasis is a neglected zoonotic parasitic disease. Currently, praziquantel is the drug of choice for the treatment of schistosomiasis, and is the only effective chemical for treatment of schistosomiasis japonica. Since its introduction in the 1970s, praziquantel has been used for large-scale chemotherapy of schistosomiasis for over 40 years. However, there have been reports pertaining to the resistance to praziquantel in schistosomes. Therefore, development of novel antischistosomal agents as alternatives of praziquantel, is of great need. Histone deacetylases and histone acetyltransferases have been recently reported to play critical roles in the growth, development and reproduction of schistosomes, and are considered as potential drug targets for the treatment of schistosomiasis. This review summarizes the latest advances of histone deacetylase and histone acetyltransferase inhibitors in the research on antischistosomal drugs, so as to provide insights into research and development of novelantischistosomal agents.
